Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | CSF1R | P07333 | 1/20 | 0.51 |
| ▸ | KIT | P10721 | 1/20 | 0.51 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.47 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4985541 | 0.86 | GAA (0.56) | MAPTGAAKDM4EPTK2BMAPK1 | |
| SCHEMBL2912399 | 0.81 | CSF1R (0.54) | MAPTGAAKDM4EPTK2BMAPK1 | |
| SCHEMBL2909520 | 0.79 | CSF1R (0.52) | MAPTGAAKDM4EPTK2BMAPK1 | |
| SCHEMBL15418562 | 0.79 | LMNA (0.49) | KDM4ELMNACHKA | |
| SCHEMBL31000469 | 0.79 | GAA (0.50) | MAPTGAAKDM4EPTK2BMAPK1 | |
| SCHEMBL2935698 | 0.79 | SIRT6 (0.56) | MAPTMAPK1CSF1RKITALDH1A1 | |
| SCHEMBL31000459 | 0.78 | GAA (0.49) | MAPTGAAKDM4EPTK2BMAPK1 | |
| SCHEMBL25541127 | 0.77 | QDPR (0.44) | CSF1RKITHDAC1HDAC2 | |
| SCHEMBL22652059 | 0.74 | SIRT6 (0.57) | MAPTMAPK1ALDH1A1SIRT6LMNA | |
| SCHEMBL2992384 | 0.73 | CSF1R (0.41) | MAPTGAAKDM4EPTK2BMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1807077-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-23 | — | — | EP | claimed |
| US-7662837-B2 | 4-cyano-1H-imidazole-2-carboxylic acid {2-cyclohex-1-enyl-4-[1-(2-dimethylamino-acetyl)-piperidin-4-yl]-phenyl}-amide; protein tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-16 | — | — | US | claimed |
| EP-1807077-A2 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-18 | — | — | EP | claimed |
| US-20060189623-A1 | Inhibitors of c-fms kinase | ILLIG CARL R | 2006-08-24 | — | — | US | claimed |
| US-20060148812-A1 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-06 | — | — | US | claimed |
| WO-2006047277-A2 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-04 | — | — | WO | claimed |
| US-10806737-B2 | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides | ARVINAS OPERATIONS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| EP-3559006-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES | Arvinas Operations, Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20180256586-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2018-09-13 | — | — | US | disclosed |
| WO-2018118598-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES | Arvinas, Inc. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-9526731-B2 | Method of inhibiting C-KIT kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-12-27 | — | — | US | disclosed |
| EP-1807077-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-23 | — | — | EP | disclosed |
| US-20150094520-A1 | METHOD OF INHIBITING C-KIT KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-02 | — | — | US | disclosed |
| EP-1951234-A2 | METHOD OF INHIBITING FLT3 KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-06 | — | — | EP | disclosed |
| US-20080051402-A1 | METHOD OF INHIBITING C-KIT KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-28 | — | — | US | disclosed |
| US-20070149572-A1 | METHOD OF INHIBITING FLT3 KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-28 | — | — | US | disclosed |
| WO-2007048088-A2 | METHOD OF INHIBITING FLT3 KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-26 | — | — | WO | disclosed |
| US-20060281788-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
| US-20060189623-A1 | Inhibitors of c-fms kinase | ILLIG CARL R | 2006-08-24 | — | — | US | disclosed |
| US-20060148812-A1 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189623-A1 | Inhibitors of c-fms kinase | MUSK, TYK2, FES | MAPT 147/4885GAA 3385/4885KDM4E 2513/4885 |
| US-20180256586-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES | MDM2, CRBN, FLT3 | MAPT 3071/4885GAA 368/4885KDM4E 2200/4885 |
| US-20060281788-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | FLT3, MCL1, CSF1R | MAPT 4541/4885GAA 977/4885KDM4E 3127/4885 |
| US-20060148812-A1 | Inhibitors of c-fms kinase | MUSK, TYK2, FES | MAPT 147/4885GAA 3385/4885KDM4E 2513/4885 |
| US-20080051402-A1 | METHOD OF INHIBITING C-KIT KINASE | KIT, CHUK, MAP3K13 | MAPT 257/4885GAA 969/4885KDM4E 1145/4885 |
| US-10806737-B2 | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides | MDM2, CRBN, FLT3 | MAPT 3071/4885GAA 368/4885KDM4E 2200/4885 |
| US-20070149572-A1 | METHOD OF INHIBITING FLT3 KINASE | FLT3, PLK1, PHKG1 | MAPT 850/4885GAA 1634/4885KDM4E 3700/4885 |
| US-20150094520-A1 | METHOD OF INHIBITING C-KIT KINASE | KIT, CHUK, MAP3K13 | MAPT 257/4885GAA 969/4885KDM4E 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.